This site is intended for health professionals only
H. Lundbeck A/S (Lundbeck) today announces the financial floor guidance for the company.
“We are pleased to continue to deliver solid profits while investing in new product launches and research and development efforts to make a positive difference for patients,” said Ulf Wiinberg, President & Chief Executive Officer at Lundbeck.
“We believe we have laid out a solid platform for the floor guidance and continue to plan for growth from 2015 and onwards,” he said.
From March 2012, as a consequence of the loss of patent protection in the United States, Lundbeck expects that Lexapro® will be exposed to generic competition, which will affect Lexapro® revenue.
In spite of the impact from the loss of Lexapro® income, Lundbeck expects to deliver solid profits during 2011-2014 and maintain its strong cash flow generation.
As part of its strategy, Lundbeck has identified and executed on a number of initiatives that will have a positive impact on revenue and profits throughout 2011-14.
The initiatives are separated into three categories: Decisions Now, R&D pipeline and business development where the goal is to optimise and maximise Lundbeck as well as invest significantly in the pipeline.
Finally, in terms of business development, the acquisition of Lundbeck Inc. in 2009 and the recent in-licensing of Sycrest® from Merck & Co., along with escitalopram in Japan, have created additional opportunities.